Tag: Bureau of Competition

The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.

The Federal Trade Commission took action to protect Americans with intellectual and developmental disabilities and their families by requiring Sevita Health (Sevita) to divest more than 100 healthcare facilities to resolve antitrust concerns surrounding its proposed $835 million acquisition of BrightSpring Health Services, Inc.’s (BrightSpring) community living business.

Under the FTC’s proposed consent order, Sevita will be required to divest 128 intermediate care facilities (ICFs), which provide IDD services, and other assets such as day-training programs. The divested facilities—which are in Indiana, Louisiana, and Texas—will be acquired by Dungarvin Group, Inc. (Dungarvin), an experienced and well-regarded operator of ICFs.

On June 10, 2026, the FTC finalized the consent order in this matter. 

The Federal Trade Commission took action to protect American patients from higher outpatient surgery costs by requiring national nonprofit health system Ascension Health Alliance (Ascension) to divest several surgery center facilities to complete its proposed $3.9 billion acquisition of AmSurg LLC.

The Federal Trade Commission will require automotive services company Valvoline Inc. and private equity firm Greenbriar Equity Fund V., L.P. (Greenbriar) to divest 45 quick-lube oil change shops to resolve antitrust concerns surrounding their $625 million deal. Main Street Auto, LLC will acquire the divested outlets from Greenbriar under the terms of the FTC’s proposed divestiture order.